MML Investors Services’s VanEck Pharmaceutical ETF PPH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$236K Buy
+2,158
New +$223K ﹤0.01% 2984
2026
Q1
Sell
-2,001
Closed -$206K 3140
2025
Q4
$206K Buy
+2,001
New +$195K ﹤0.01% 2866
2025
Q3
Sell
-2,511
Closed -$221K 2968
2025
Q2
$221K Buy
2,511
+52
+2% +$4.51K ﹤0.01% 2624
2025
Q1
$224K Sell
2,459
-300
-11% -$27K ﹤0.01% 2477
2024
Q4
$238K Sell
2,759
-1,056
-28% -$95.5K ﹤0.01% 2398
2024
Q3
$362K Sell
3,815
-1,003
-21% -$95.3K ﹤0.01% 2048
2024
Q2
$441K Buy
4,818
+1,581
+49% +$141K ﹤0.01% 1868
2024
Q1
$294K Buy
+3,237
New +$283K ﹤0.01% 2121
2023
Q3
Sell
-4,227
Closed -$333K 2357
2023
Q2
$333K Buy
4,227
+424
+11% +$33.2K ﹤0.01% 1879
2023
Q1
$295K Sell
3,803
-619
-14% -$47.7K ﹤0.01% 1685
2022
Q4
$344K Buy
4,422
+359
+9% +$26.5K ﹤0.01% 1688
2022
Q3
$273K Buy
+4,063
New +$299K ﹤0.01% 1744

Other funds holding PPH

MML Investors Services's PPH Position: Q2 2026 in Review

MML Investors Services opened a new position in VanEck Pharmaceutical ETF (PPH) in Q2 2026: 2,158 shares worth $236K. The stake represents ﹤0.01% of the portfolio and ranks #2984 among its holdings. This is a return to the name: MML Investors Services previously reported a position in PPH as recently as Q4 2025.

MML Investors Services first reported a position in PPH in Q3 2022 and has held it in 12 quarters since. The position peaked at $441K in Q2 2024. 80 funds tracked by Wall St. Rank hold PPH as of Q2 2026.

  • MML Investors Services held 2,158 shares of VanEck Pharmaceutical ETF worth $236K as of Q2 2026.
  • VanEck Pharmaceutical ETF was a new MML Investors Services position in Q2 2026.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of MML Investors Services's portfolio in Q2 2026, its #2984 holding.
  • MML Investors Services first reported a position in VanEck Pharmaceutical ETF in Q3 2022 and has held it in 12 quarters since.
  • MML Investors Services's VanEck Pharmaceutical ETF position peaked at $441K in Q2 2024.
  • 80 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q2 2026.

Based on MML Investors Services's 13F filing for Q2 2026, filed 7 Aug 2026.